Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects

NCT01287858 | Completed Phase 1

• 1 other identifier: AC430-001
• Study Type: interventional
• Target: 88
• Locations: 1 country
• Sites: 1

Brief Summary

AC430 will be administered, orally under fasting conditions (fasting 4 hours before and 2 hours after dosing) with approximately 240 mL of water either once daily or twice daily. It is designed to assess the safety, tolerability, and pharmacokinetics of single and multiple oral doses of AC430.

Conditions

Rheumatoid Arthritis

Outcome Measures

Primary Outcomes (1)

• Assess the safety, tolerability, and pharmacokinetics of single and multiple oral doses of AC430.

  * Number of participants with adverse events as measurement of safety and tolerability of AC430. \[Time frame: 1-28 days\] * Maximum concentration (Cmax) for AC430 in plasma (measured in ng/mL) \[Time frame: 1-28 days\] * Tmax = Time of maximum concentration of AC430 in plasma (hr) \[Time frame: 1-28 days\] * AUC = Area under the curve from the time of dosing extrapolated to infinity (ng.hr/mL) \[Time frame: 1-28 days\] * Urine: amount of AC430 excreted in urine (Ae0-48), renal clearance (CLr) and fraction of drug excreted in urine (Fe). \[Time frame: 1-28 days\]

  6 months

Secondary Outcomes (1)

• Determine the pharmacodynamic effects of single and multiple oral doses of AC430.

  Measured at specific timepoints prior to and following dosing regimen.

Study Arms (2)

Placebo

PLACEBO COMPARATOR

Placebo

Drug: AC430

AC430

ACTIVE COMPARATOR

AC430

Drug: AC430

Interventions

AC430 DRUG

Healthy volunteers will either receive AC430 or placebo.

AC430; Placebo

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy normal males and females, age 18 to 45, inclusive, at the time of consent
• Able to communicate effectively in the English language
• Able to provide valid, written informed consent
• Able to swallow up to 20 capsules of study drug
• BMI (body mass index) ranging between 18 and 30 kg/m2, inclusive
• Minimum weight of 50 kg
• Serum Creatinine ≤ ULN (upper limit of normal) and estimated creatinine clearance at screening of ≥ 80 mL/min per the Cockcroft-Gault equation
• Total serum bilirubin ≤ ULN (may be repeated to confirm eligibility)
• Serum aspartate transaminase (AST) and alanine transaminase (ALT) ≤ ULN (may be repeated to confirm eligibility)
• Male subjects must either be sterile or agree to use from Check-in until 90 days following the last dose of AC430, an acceptable form of birth control.
• Female participants must be either of non-child-bearing potential or agree to use an acceptable form of birth control.

You may not qualify if:

• History of clinically significant drug allergy
• Participation in another clinical trial with receipt of an Investigational Product within 90 days before dose administration (or 5 half-lives, whichever is longer)
• Major surgery within 90 days before study enrollment
• Use of prescription, over the counter, or herbal medications or supplements, including oral contraceptives within 14 days of check-in
• A history of drug abuse or a history of alcohol abuse within 1 year prior to Screening
• Current or recent (within 30 days before enrollment) use of tobacco or nicotine products
• Consumption of alcohol containing beverages \> an average of 14 drinks per week or unwillingness to refrain from ethanol consumption while confined to the study unit
• Inadequate venous access that would interfere with obtaining blood samples
• Recipients of blood transfusion or transfusion of blood or plasma products, within 90 days before study drug administration
• Donation of blood ≥ 500 mL within 2 months before study drug administration
• History or positive laboratory evidence of Human immunodeficiency virus (HIV), Hepatitis B antigen and antibody, or Hepatitis C, or history of Tuberculosis (TB) infection, or a positive result for Quantiferon Gold test
• Prolonged average of the corrected QTc by Fridericia's correction factor (QTcF) interval on screening electrocardiogram (ECG) triplicate (≥ 450 ms for males and ≥ 470 ms for females)
• Abnormal laboratory values that are considered clinically significant by the Investigator
• History of cancer
• History of eating disorders within the past 3 months

Sponsors & Collaborators

• Daiichi Sankyo: lead

Study Sites (1)

Covance Clinical Research Unit

Madison, Wisconsin, 53718, United States

Location

MeSH Terms

Conditions

Arthritis, Rheumatoid

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• Guy Gammon, MB BS, MRCP

  Interim Chief Medical Officer / Ambit Biosciences Corporation

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 12, 2011
• First Posted: February 2, 2011
• Study Start: November 1, 2010
• Primary Completion: June 1, 2011
• Study Completion: June 1, 2011
• Last Updated: November 2, 2015

Record last verified: 2015-10

Locations

US (1)